Traditional therapy for cancer treatments have long been chemotherapy infusion drugs, oral chemo pills, immunotherapy, surgery, and radiation. A new method of targeting cancer cells in treating late-stage Non-Small Cell Lung Cancer (NSCLC) is under investigation through Charlotte oncologists Justin Favaro, M.D. and Nasfat Shehadeh M.D. at Oncology Specialists of Charlotte. They are excited to announce the beginning of enrollment for the Novocure KEYNOTE-B36 study; the first site pen to providing this trial in the United States. This clinical trial is promising for lung cancer patients not progressing on current therapies and other options are not viable.
The KEYNOTE B36 study is a pilot, open-label study designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T. Subjects who meet eligibility through their physician can enroll and be set up on the device which includes four adhesive patches, two on the torso and two on the back, with electrodes connected to the TTFields which administers electrical interference to the cancer cells. The device is worn throughout the day and is portable and light so that it may be taken anywhere the patient needs to go.
About the KEYNOTE B36 Study Design:
Study subjects use the device concomitant with pembrolizumab which is a standard immunotherapy agent delivered intravenously, for first line treatment of advanced or metastatic intrathoracic NSCLC. The study is for newly diagnosed advanced or metastatic intrathoracic NSCLC. For a detailed outlay of the KEYNOTE B36 study and a picture of the device, go to The KEYNOTE B36 Study | Novocure Trials
Lung Cancer Statistics:
Lung Cancer is the most common cause of cancer-related deaths worldwide, and NSCLC accounts for around 85% of all lung cancers. There are approximately 193,000 new NSCLC cases each year in the U.S.
Since 2000, Oncology Specialists of Charlotte (OSC) has provided leading-edge, compassionate care for cancer and blood disorders. OSC’s physicians and staff take part in multi-disciplinary care, clinical trials, and peer boards at the hospital. The OSC team understands the profound impact of cancer on the lives of people and their families, and the practice maintains access to the latest, best treatment options. For more information, go to Cancer Specialists in Charlotte | Cancer & Blood Disorder Experts in Charlotte, NC (oncologycharlotte.com)
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE B36 Trial, here Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer – Novocure
FOR A COMMENT FROM ONCOLOGISTS FAVARO AND/OR SHEHADEH, PLEASE USE CONTACT INFO PROVIDED